Verona, 5th March 2015: Techorizon, today announced the launch of FeRMI, a unique electronic application which brings the conduct of clinical trial feasibility studies into the 21st Century. At the same time, Techorizon also launched a new technically advanced website.
Clinical research projects are often characterized by delays and cost overruns. A crucial step in mitigating against these risks during planning is a detailed feasibility study. To date, such feasibility studies have been largely paper or email based and data have been time consuming to process and analyze. Furthermore, the knowledge base of prior feasibility studies is typically not integrated with the process, and the database of prior investigator site contacts resides as a separate, distinct entity.
Named after the length scale used in nuclear physics in recognition of the detailed data collected, FeRMI creates an entirely integrated, electronic approach to the conduct of feasibility studies and promotes faster, more effective study planning. Each step of the process is managed electronically, with data collection from sites completed via highly customizable online surveys which include real time error checks. The powerful investigator database module speeds selection of potential sites and tracks previous contacts and historical study performance. A powerful real-time reporting module allows users to track trends emerging from the feasibility study whilst in progress, and ultimately to make better decisions about site selection.
‘FeRMI revolutionizes clinical project planning by allowing our clients to conduct faster, more detailed, more accurate feasibility studies’, noted Silvio Severini, Managing Director of Techorizon. ‘FeRMI adds to our Th-eClinical suite and is entirely unique, the first technology application to provide an end-to-end solution for the conduct of feasibility studies’.
About Techorizon: A quality-driven technology company with ISO9001:2008 certification, Techorizon is headquartered in Verona, Italy with North American offices in Cambridge, MA. Services are delivered through Techorizon’s state-of-the-art technology infrastructure maintained in Verona. All Techorizon products are fully validated to GAMP 5 standards as well as being 21 CFR Part 11 compliant. Launched in 2009 as a separate company, Techorizon had previously provided technology services exclusively to CROMSOURCE, a leading international CRO. Techorizon serves clients of all sizes within the clinical research and wider Healthcare industry.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.